ArticleMaterials today. Bio2026
3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work aimed to develop and characterize a three-dimensional culture platform that recreates the tumor microenvironment of multiple myeloma cells (MMCs), focusing on how atypical plasma cells (aPCs) interact with other bone marrow cells and extracellular matrix (ECM) components to develop drug resistance. The biomimetic platform consists of a static system based on a conical agarose geometry that facilitates the agglomeration and proliferation of aPCs. Magnetic alginate microgels, manufactured by microfluidics, configure the ECM through a layer-by-layer functionalization with collagen, hyaluronic acid, chondroitin sulfate, and heparin. In addition, bone marrow mesenchymal stem cell (BMMSC) pellets were integrated to simulate direct and indirect interactions between BMMSCs and MMCs. The platform has been validated with three lines of MMCs (RPMI8226, MM1S, U266) and the patients' mononuclear cell fraction collected from bone marrow aspirates extracted in two Spanish Hospitals. The microgel analysis aimed to verify stability and to characterize the presence of the different coatings. Biological studies have investigated the proliferation and resistance to drug treatments in MM cell lines. In addition, patient-derived cells were cultured for up to 14 days to study the survival and possible immunophenotypic changes of the atypical plasma cell (aPC) fraction.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.